If this message does not display properly, please click here to launch your browser
| Payer Perspectives of Biosimilars: Priorities, Barriers to Entry and Opportunities
— An Analyst Call from Decision Resources’ Biosimilars Advisory Service | |||
As part of our Biosimilars Advisory Service, Decision Resources is offering an exclusive analyst call entitled Payer Perspectives of Biosimilars: Priorities, Barriers to Entry and Opportunities. This analyst call is open ONLY to subscribers of Decision Resources’ Biosimilars Advisory Service. Please contact us to learn how you can purchase this service and attend the analyst call. Despite being only a 15-30 percent initial discount to branded biologics, biosimilars will afford payers an important opportunity to reduce pharmaceutical expenditures. The extent to which payers actively promote the use of biosimilars will affect uptake of these agents and concomitant erosion of brand sales. However, the mechanisms by which payers will promote biosimilars will vary by drug class, treatment setting and reimbursement environment. Based on Decision Resources’ Biosimilars Advisory Service: U.S. and EU Payer Perspectives, this analyst call will answer the following questions:
Registration: Biosimilars Advisory Service Analyst Call Payer Perspectives of Biosimilars: Priorities, Barriers to Entry and Opportunities July 27, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase the Biosimilars Advisory Service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||
